Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates ofCandida species

1988 ◽  
Vol 7 (1) ◽  
pp. 80-81 ◽  
Author(s):  
E. D. Spitzer ◽  
S. J. Travis ◽  
G. S. Kobayashi
Keyword(s):  
Amphotericin B ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity

In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies

2020 ◽  
Vol 75 (12) ◽  
pp. 3582-3585
Author(s):  
Olga Rivero-Menendez ◽  
Manuel Cuenca-Estrella ◽  
Ana Alastruey-Izquierdo
Keyword(s):  
Amphotericin B ◽  
Susceptibility Testing ◽  
Antifungal Susceptibility ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Scedosporium Apiospermum ◽  
In Vitro Activity ◽  
Scedosporium Dehoogii ◽  
Scedosporium Species

Abstract Objectives To evaluate the in vitro activity of olorofim, a new broad-spectrum antifungal with a novel mechanism of action, against a collection of 123 Spanish clinical isolates belonging to five Scedosporium species and Lomentospora prolificans. Methods The activity of olorofim against Scedosporium apiospermum (n = 30), Scedosporium boydii (n = 30), Scedosporium ellipsoideum (n = 10), Scedosporium aurantiacum (n = 20), Scedosporium dehoogii (n = 3) and Lomentospora prolificans (n = 30) was compared with that of amphotericin B, voriconazole, isavuconazole and micafungin by performing EUCAST and CLSI reference methods for antifungal susceptibility testing. Results Amphotericin B and isavuconazole showed MICs ≥2 mg/L for all the species evaluated and voriconazole was moderately active (GM, MIC50 and MIC90 values ≤2 mg/L) against all of them except L. prolificans. Micafungin was effective against S. apiospermum complex strains, but exhibited elevated MECs for S. dehoogii and S. aurantiacum. Olorofim showed low MICs for all the Scedosporium strains tested (GM values were lower than 0.130 and 0.339 by the EUCAST method and the CLSI method, respectively, for all of the species), including those belonging to the MDR species L. prolificans, for which GM values were 0.115 and 0.225 mg/L by the EUCAST method and the CLSI method, respectively, while the GMs for the rest of the antifungals evaluated were higher than 3.732 mg/L using both methodologies. Conclusions Olorofim displayed promising in vitro activity against the Scedosporium and L. prolificans strains tested, some of which have reduced susceptibility to the antifungals that are currently in use.

scholarly journals Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus

1998 ◽  
Vol 42 (4) ◽  
pp. 531-533 ◽  
Author(s):  
M. Cuenca-Estrella ◽  
J. L. Rodriguez-Tudela ◽  
E. Mellado ◽  
J. V. Martinez-Suarez ◽  
A. Monzon
Keyword(s):  
Aspergillus Fumigatus ◽  
Amphotericin B ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity

scholarly journals In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents

2007 ◽  
Vol 51 (7) ◽  
pp. 2587-2590 ◽  
Author(s):  
Nikolaos G. Almyroudis ◽  
Deanna A. Sutton ◽  
Annette W. Fothergill ◽  
Michael G. Rinaldi ◽  
Shimon Kusne
Keyword(s):  
Amphotericin B ◽  
Clinical Efficacy ◽  
Antifungal Agents ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Cunninghamella Bertholletiae

ABSTRACT We evaluated the in vitro susceptibilities of 217 zygomycetes to amphotericin B, ketoconazole, fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, and flucytosine. The significant in vitro activity of posaconazole against several species appears to support its reported clinical efficacy. Decreased susceptibility to amphotericin B was noted with Cunninghamella bertholletiae.

scholarly journals In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp.

2015 ◽  
Vol 64 (3) ◽  
pp. 309-311 ◽  
Author(s):  
Fabrice Compain ◽  
Françoise Botterel ◽  
Emilie Sitterlé ◽  
André Paugam ◽  
Marie-Elisabeth Bougnoux ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity

scholarly journals In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.

1997 ◽  
Vol 41 (5) ◽  
pp. 1124-1126 ◽  
Author(s):  
K L Oakley ◽  
C B Moore ◽  
D W Denning
Keyword(s):  
Amphotericin B ◽  
Drug Concentration ◽  
Antifungal Agent ◽  
Aspergillus Terreus ◽  
Geometric Mean ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Reproducibility Study

In this study, we investigated the in vitro activity of SCH-56592 (SCH), a new triazole antifungal agent. We compared the activity of SCH with those of itraconazole (ITZ) and amphotericin B (AB) against 60 clinical isolates of Aspergillus spp. by using a microtiter format. Incubation was done at 37 degrees C for 48 h, and MIC endpoints (no growth) were read visually. The medium used for all of the drugs was RPMI 1640 buffered with morpholinepropanesulfonic acid (MOPS) and supplemented with 2% glucose. MICs and minimum fungicidal concentrations (MFCs; killing of > or = 99.99%) were measured for all isolates. The geometric mean (GM) MICs and ranges (in micrograms per milliliter) were as follows: SCH, 0.09 and < or = 0.01 to 1; ITZ, 0.25 and 0.06 to 32; AB, 1.46 and 0.25 to 32. Aspergillus terreus (n = 7) was markedly more susceptible to SCH (GM, 0.05 microg/ml) and ITZ (GM, 0.07 microg/ml) than to AB (GM, 8.8 microg/ml). For all isolates, the GM MFCs and ranges (in micrograms per milliliter) were as follows: SCH, 3.64 and 0.125 to 16; ITZ, 15.09 and 0.125 to 32; AB, 10.3 and 1 to 32. In the drug concentration range tested, 71, 32, and 64% of the isolates against which SCH, ITZ, and AB, respectively, were tested were killed. A reproducibility study was performed with 20% of the isolates; for 11 of the 12 isolates retested, the MIC was the same or within 1 well of the original MIC of each drug. Therefore, in vitro mould testing of SCH is feasible and reproducible. SCH was found to be very active against all species of Aspergillus and at lower concentrations than either ITZ or AB.

scholarly journals In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp

2002 ◽  
Vol 46 (6) ◽  
pp. 1723-1727 ◽  
Author(s):  
M. A. Pfaller ◽  
S. A. Messer ◽  
R. J. Hollis ◽  
R. N. Jones ◽  
D. J. Diekema
Keyword(s):  
Candida Albicans ◽  
Amphotericin B ◽  
Antifungal Agents ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Candida Spp ◽  
Medical Centers ◽  
Dose Dependent

ABSTRACT The in vitro activities of ravuconazole and voriconazole were compared with those of amphotericin B, flucytosine (5FC), itraconazole, and fluconazole against 6,970 isolates of Candida spp. obtained from over 200 medical centers worldwide. Both ravuconazole and voriconazole were very active against all Candida spp. (MIC at which 90% of the isolates tested are inhibited [MIC90], 0.25 μg/ml; 98% of MICs were ≤1 μg/ml); however, a decrease in the activities of both of these agents was noted among isolates that were susceptible-dose dependent (fluconazole MIC, 16 to 32 μg/ml) and resistant (MIC, ≥ 64 μg/ml) to fluconazole. Candida albicans was the most susceptible species (MIC90 of both ravuconazole and voriconazole, 0.03 μg/ml), and C. glabrata was the least susceptible species (MIC90, 1 to 2 μg/ml). Ravuconazole and voriconazole were each more active in vitro than amphotericin B, 5FC, itraconazole, and fluconazole against all Candida spp. and were the only agents with good in vitro activity against C. krusei. These results provide further evidence for the spectrum and potency of ravuconazole and voriconazole against a large and geographically diverse collection of Candida spp.

scholarly journals In Vitro Activity of the New Triazole BMS-207147 againstAspergillus Species in Comparison with Itraconazole and Amphotericin B

2000 ◽  
Vol 44 (2) ◽  
pp. 441-443 ◽  
Author(s):  
Caroline B. Moore ◽  
Caroline M. Walls ◽  
David W. Denning
Keyword(s):  
Aspergillus Fumigatus ◽  
Amphotericin B ◽  
Geometric Mean ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
High Concentrations

ABSTRACT The in vitro activity of BMS-207147 against 80 clinical isolates ofAspergillus was compared with that of itraconazole and amphotericin B, using a validated microtiter method. Geometric mean MICs (in μg/ml) were as follows: 1.71 for BMS-207147, 0.67 for itraconazole, and 0.63 for amphotericin B. The range of concentrations of each drug was 0.125 to >16 μg/ml. Aspergillus fumigatus was significantly more susceptible to BMS-207147 (P < 0.05) than A. terreusand A. flavus. No BMS-207147-resistant A. fumigatus isolates were identified, though eight itraconazole-resistant (MIC, >8 μg/ml) isolates were. BMS-207147 is active against Aspergillus spp. at slightly high concentrations compared with itraconazole and amphotericin B.

scholarly journals In Vitro Activities of Approved and Investigational Antifungal Agents against 44 Clinical Isolates of Basidiomycetous Fungi

2001 ◽  
Vol 45 (2) ◽  
pp. 633-635 ◽  
Author(s):  
Gloria M. González ◽  
Deanna A. Sutton ◽  
Elizabeth Thompson ◽  
Rolando Tijerina ◽  
Michael G. Rinaldi
Keyword(s):  
Amphotericin B ◽  
Antifungal Agents ◽  
Schizophyllum Commune ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Bjerkandera Adusta

ABSTRACT The in vitro activity of amphotericin B, fluconazole, flucytosine, itraconazole, voriconazole, and posaconazole was evaluated against 44 clinical isolates of filamentous basidiomycetous fungi. No statistically significant differences were noted betweenSchizophyllum commune (n = 5),Coprinus species (n = 8),Bjerkandera adusta (n = 14), and sterile, uncharacterized basidiomycetes (n = 17).

Sign in / Sign up

Export Citation Format

Share Document